FindTrial
Sign In

Azithromycin in paediatric nephrotic syndrome

Effect of addition of Azithromycin to routine treatment regime on time to remission in Paediatric Primary Nephrotic Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039753
Enrollment
70
Registered
2022-01-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality

Interventions

Intervention1: AZITHROMYCIN: APART FROM STEROID THERAPY FOR RELAPSE INTERVENTION GROUP WILL ALSO RECEIVE ORAL AZITHROMYCIN AT 10MG PER KG PER DAY FOR 3 DAYS Control Intervention1: PLACEBO: Apart from

Sponsors

MLN MEDICAL COLLEGE PRAYAGRAJ
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Known cases of Nephrotic Syndrome in relapse and new cases of Nephrotic Syndrome

Exclusion criteria

Exclusion criteria: 1 Patients with chronic infections 2 Steroid Resistant Nephrotic Syndrome 3 Hypersensitivity to Macrolides

Design outcomes

Primary

MeasureTime frame
TIME TO ACHEIVE REMISSIONTimepoint: number of days to achieve remission—

Secondary

MeasureTime frame
1 time to next relapse 2 side effect of azithromycin therapyTimepoint: 1 year—

Countries

India

Contacts

Public ContactDR Rajat Singh

MLN MEDICAL COLLEGE PRAYAGRAJ

anubhashrivastava@rediffmail.com9236804326

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026